Red List

GLUEMonte Rosa Therapeutics, Inc.

Healthcare · Biotechnology · small-cap ($1.4B)
-42.6%
from rolling 252-day high of $25.77 set 2026-01-08 · 224d ago
Current
$14.78
Decline depth
-42.6%
Decline σ
5.8σ
TFC
3/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Since tracking began

$GLUE has been tracked since 2026-03-01. It was down 28.2% from its 52-week high then — now down -42.6%.

That's 16.3 percentage points deeper than the day it joined.

Decline from the 52-week high as it stood on 2026-03-02 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.

Structural break signals

GLUE qualifies for the Red List on decline depth.

Decline depth
-42.6%
From rolling 252-day high of $25.77, 224d ago. Past the 40% Red List threshold.
Time-frame continuity
3/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3. Past the 3/5 Watch threshold.
Decline sigma
5.8σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (6.71% per day). Past the ≥4σ Watch threshold.

The structural read

What price action says about GLUE.

GLUE qualifies for the Red List on decline depth — down -42.6% from its rolling 252-day high. Past the 40% threshold, the deepest tier in the taxonomy.

Cross-confirmation: also showing 3/5 bearish time frames.

Cross-confirmation: decline sigma also reads 5.8σ over 20 bars.

Earnings on file: 2026-05-07. Tiering is unaffected by earnings dates — listings reflect price structure only.

Questions about GLUE

What people ask.

Why is GLUE on Broken Stocks?

GLUE qualifies for the Red List on decline depth. It is down -42.6% from its rolling 252-day high of $25.77, set on 2026-01-08 — 224d ago.

Is GLUE a falling knife?

Not by the strict technical definition. GLUE is down -42.6% from its 52-week high, but that high was set 224d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. GLUE is still on the Red List for decline depth, but the freshness component of a falling knife is missing.

Is GLUE a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is GLUE trading inside its 52-week range?

At $14.78, GLUE sits 49.2% of the way from its 52-week low ($4.12) to its 52-week high ($25.77). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has GLUE been declining?

The current 42.6% decline accrued over 224d, which annualizes to roughly -69.4% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does GLUE compare to its sector?

There are 143 other Healthcare tickers on Broken Stocks: 69 Red, 35 Amber, 39 Watch, with 50 showing recovering structural signals. Median sector decline is -36.1% — GLUE's decline is deeper than the sector median.

Does GLUE's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-05-07) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.